25 XP   0   0   10

Neuren Pharmaceuticals Ltd
Buy, Hold or Sell?

Let's analyse Neuren Pharmaceuticals Ltd together

PenkeI guess you are interested in Neuren Pharmaceuticals Ltd. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Neuren Pharmaceuticals Ltd. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Neuren Pharmaceuticals Ltd

I send you an email if I find something interesting about Neuren Pharmaceuticals Ltd.

Quick analysis of Neuren Pharmaceuticals Ltd (30 sec.)










What can you expect buying and holding a share of Neuren Pharmaceuticals Ltd? (30 sec.)

How much money do you get?

How much money do you get?
A$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
A$0.32
Expected worth in 1 year
A$0.39
How sure are you?
60.0%

+ What do you gain per year?

Total Gains per Share
A$0.07
Return On Investment
0.4%

For what price can you sell your share?

Current Price per Share
A$19.71
Expected price per share
A$15.55 - A$24.22
How sure are you?
50%
3rd Party Ad. No recommendation by Penke. PLUS is ad-free.

1. Valuation of Neuren Pharmaceuticals Ltd (5 min.)




Live pricePrice per Share (EOD)

A$19.71

Intrinsic Value Per Share

A$-0.22 - A$1.35

Total Value Per Share

A$0.10 - A$1.67

2. Growth of Neuren Pharmaceuticals Ltd (5 min.)




Is Neuren Pharmaceuticals Ltd growing?

Current yearPrevious yearGrowGrow %
How rich?$27.1m$25.6m$1.5m5.6%

How much money is Neuren Pharmaceuticals Ltd making?

Current yearPrevious yearGrowGrow %
Making money$1.5m-$5m$6.5m427.5%
Net Profit Margin16.3%-18,890.2%--

How much money comes from the company's main activities?

3. Financial Health of Neuren Pharmaceuticals Ltd (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#571 / 1045

Most Revenue
#297 / 1045

Most Profit
#127 / 1045

Most Efficient
#95 / 1045
3rd Party Ad. No recommendation by Penke. PLUS is ad-free.

What can you expect buying and holding a share of Neuren Pharmaceuticals Ltd? (5 min.)

Welcome investor! Neuren Pharmaceuticals Ltd's management wants to use your money to grow the business. In return you get a share of Neuren Pharmaceuticals Ltd.

What can you expect buying and holding a share of Neuren Pharmaceuticals Ltd?

First you should know what it really means to hold a share of Neuren Pharmaceuticals Ltd. And how you can make/lose money.

Speculation

The Price per Share of Neuren Pharmaceuticals Ltd is A$19.71. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Neuren Pharmaceuticals Ltd.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Neuren Pharmaceuticals Ltd, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is A$0.32. Based on the TTM, the Book Value Change Per Share is A$0.02 per quarter. Based on the YOY, the Book Value Change Per Share is A$0.12 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is A$0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Neuren Pharmaceuticals Ltd.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 A$% of Price per ShareA$% of Price per ShareA$% of Price per ShareA$% of Price per ShareA$% of Price per Share
Usd Eps0.000.0%0.000.0%-0.04-0.2%-0.02-0.1%-0.03-0.2%
Usd Book Value Change Per Share0.010.1%0.010.1%0.080.4%0.030.1%0.020.1%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share0.010.1%0.010.1%0.080.4%0.030.1%0.020.1%
Usd Price Per Share5.19-5.19-2.46-2.20-1.34-
Price to Earnings Ratio5,605.87-5,605.87--62.76-1,110.87-567.56-
Price-to-Total Gains Ratio441.56-441.56-32.49-96.46-51.04-
Price to Book Ratio24.80-24.80-12.46-14.95-10.43-
Price-to-Total Gains Ratio441.56-441.56-32.49-96.46-51.04-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share12.862746
Number of shares77
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.010.03
Usd Total Gains Per Share0.010.03
Gains per Quarter (77 shares)0.901.95
Gains per Year (77 shares)3.627.82
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
104-608-2
207-20166
3011202314
4014603122
50181003930
60221404738
70251805546
80292206354
90332607062
100363007870

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share1.00.00.0100.0%1.02.00.033.3%2.03.00.040.0%3.07.00.030.0%4.017.02.017.4%
Book Value Change Per Share1.00.00.0100.0%3.00.00.0100.0%4.01.00.080.0%6.04.00.060.0%11.012.00.047.8%
Dividend per Share0.00.01.00.0%0.00.03.00.0%0.00.05.00.0%0.00.010.00.0%0.00.023.00.0%
Total Gains per Share1.00.00.0100.0%3.00.00.0100.0%4.01.00.080.0%6.04.00.060.0%11.012.00.047.8%
3rd Party Ad. No recommendation by Penke. PLUS is ad-free.

Fundamentals of Neuren Pharmaceuticals Ltd

About Neuren Pharmaceuticals Ltd

Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. Its lead product is trofinetide, which is in Phase III clinical trial for the treatment of Rett syndrome, as well as has completed Phase II clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase I clinical trial for the treatment of Phelan-McDermid, Angelman, Pitt Hopkins, and Prader-Will syndromes. In addition, it provides development services; and holds loan funded shares. Neuren Pharmaceuticals Limited was incorporated in 2001 and is based in Camberwell, Australia.

Fundamental data was last updated by Penke on 2024-02-21 10:51:03.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge profit.
Using its assets, the company is efficient in making profit.
Using its investors money, the company is less efficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd Party Ad. No recommendation by Penke. PLUS is ad-free.

1.1. Profitability of Neuren Pharmaceuticals Ltd.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Neuren Pharmaceuticals Ltd earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Neuren Pharmaceuticals Ltd to the Biotechnology industry mean.
  • A Net Profit Margin of 16.3% means that $0.16 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Neuren Pharmaceuticals Ltd:

  • The MRQ is 16.3%. The company is making a huge profit. +2
  • The TTM is 16.3%. The company is making a huge profit. +2
Trends
Current periodCompared to+/- 
MRQ16.3%TTM16.3%0.0%
TTM16.3%YOY-18,890.2%+18,906.5%
TTM16.3%5Y-5,536.2%+5,552.4%
5Y-5,536.2%10Y-2,263.9%-3,272.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ16.3%-188.7%+205.0%
TTM16.3%-211.4%+227.7%
YOY-18,890.2%-286.5%-18,603.7%
5Y-5,536.2%-469.5%-5,066.7%
10Y-2,263.9%-609.8%-1,654.1%
1.1.2. Return on Assets

Shows how efficient Neuren Pharmaceuticals Ltd is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Neuren Pharmaceuticals Ltd to the Biotechnology industry mean.
  • 5.5% Return on Assets means that Neuren Pharmaceuticals Ltd generated $0.05 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Neuren Pharmaceuticals Ltd:

  • The MRQ is 5.5%. Using its assets, the company is efficient in making profit. +1
  • The TTM is 5.5%. Using its assets, the company is efficient in making profit. +1
Trends
Current periodCompared to+/- 
MRQ5.5%TTM5.5%0.0%
TTM5.5%YOY-19.3%+24.8%
TTM5.5%5Y-22.2%+27.6%
5Y-22.2%10Y-44.6%+22.4%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ5.5%-12.7%+18.2%
TTM5.5%-12.4%+17.9%
YOY-19.3%-11.4%-7.9%
5Y-22.2%-13.9%-8.3%
10Y-44.6%-15.6%-29.0%
1.1.3. Return on Equity

Shows how efficient Neuren Pharmaceuticals Ltd is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Neuren Pharmaceuticals Ltd to the Biotechnology industry mean.
  • 5.7% Return on Equity means Neuren Pharmaceuticals Ltd generated $0.06 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Neuren Pharmaceuticals Ltd:

  • The MRQ is 5.7%. Using its investors money, the company is less efficient in making profit.
  • The TTM is 5.7%. Using its investors money, the company is less efficient in making profit.
Trends
Current periodCompared to+/- 
MRQ5.7%TTM5.7%0.0%
TTM5.7%YOY-19.7%+25.4%
TTM5.7%5Y-22.8%+28.5%
5Y-22.8%10Y-56.3%+33.5%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ5.7%-16.3%+22.0%
TTM5.7%-16.2%+21.9%
YOY-19.7%-14.7%-5.0%
5Y-22.8%-19.1%-3.7%
10Y-56.3%-20.0%-36.3%
3rd Party Ad. No recommendation by Penke. PLUS is ad-free.

1.2. Operating Efficiency of Neuren Pharmaceuticals Ltd.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Neuren Pharmaceuticals Ltd is operating .

  • Measures how much profit Neuren Pharmaceuticals Ltd makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Neuren Pharmaceuticals Ltd to the Biotechnology industry mean.
  • An Operating Margin of -11.0% means the company generated $-0.11  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Neuren Pharmaceuticals Ltd:

  • The MRQ is -11.0%. The company is operating very inefficient. -2
  • The TTM is -11.0%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-11.0%TTM-11.0%0.0%
TTM-11.0%YOY-27,897.6%+27,886.5%
TTM-11.0%5Y-7,469.2%+7,458.2%
5Y-7,469.2%10Y-5,425.8%-2,043.5%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-11.0%-302.9%+291.9%
TTM-11.0%-220.2%+209.2%
YOY-27,897.6%-288.3%-27,609.3%
5Y-7,469.2%-461.8%-7,007.4%
10Y-5,425.8%-610.0%-4,815.8%
1.2.2. Operating Ratio

Measures how efficient Neuren Pharmaceuticals Ltd is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 1.11 means that the operating costs are $1.11 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Neuren Pharmaceuticals Ltd:

  • The MRQ is 1.110. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.110. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.110TTM1.1100.000
TTM1.110YOY278.976-277.865
TTM1.1105Y80.214-79.104
5Y80.21410Y70.109+10.105
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.1102.963-1.853
TTM1.1103.251-2.141
YOY278.9763.828+275.148
5Y80.2145.978+74.236
10Y70.1097.505+62.604
3rd Party Ad. No recommendation by Penke. PLUS is ad-free.

1.3. Liquidity of Neuren Pharmaceuticals Ltd.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Neuren Pharmaceuticals Ltd is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 25.77 means the company has $25.77 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Neuren Pharmaceuticals Ltd:

  • The MRQ is 25.772. The company is very able to pay all its short-term debts. +2
  • The TTM is 25.772. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ25.772TTM25.7720.000
TTM25.772YOY49.868-24.096
TTM25.7725Y29.604-3.832
5Y29.60410Y18.768+10.836
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ25.7724.010+21.762
TTM25.7724.478+21.294
YOY49.8685.577+44.291
5Y29.6046.222+23.382
10Y18.7686.568+12.200
1.3.2. Quick Ratio

Measures if Neuren Pharmaceuticals Ltd is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Neuren Pharmaceuticals Ltd to the Biotechnology industry mean.
  • A Quick Ratio of 24.59 means the company can pay off $24.59 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Neuren Pharmaceuticals Ltd:

  • The MRQ is 24.594. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 24.594. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ24.594TTM24.5940.000
TTM24.594YOY47.580-22.986
TTM24.5945Y41.730-17.136
5Y41.73010Y25.373+16.357
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ24.5943.566+21.028
TTM24.5944.169+20.425
YOY47.5805.472+42.108
5Y41.7306.097+35.633
10Y25.3736.383+18.990
3rd Party Ad. No recommendation by Penke. PLUS is ad-free.

1.4. Solvency of Neuren Pharmaceuticals Ltd.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Neuren Pharmaceuticals Ltd assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Neuren Pharmaceuticals Ltd to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.04 means that Neuren Pharmaceuticals Ltd assets are financed with 3.9% credit (debt) and the remaining percentage (100% - 3.9%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Neuren Pharmaceuticals Ltd:

  • The MRQ is 0.039. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.039. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.039TTM0.0390.000
TTM0.039YOY0.020+0.019
TTM0.0395Y0.040-0.002
5Y0.04010Y0.098-0.058
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0390.332-0.293
TTM0.0390.329-0.290
YOY0.0200.262-0.242
5Y0.0400.371-0.331
10Y0.0980.380-0.282
1.4.2. Debt to Equity Ratio

Measures if Neuren Pharmaceuticals Ltd is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Neuren Pharmaceuticals Ltd to the Biotechnology industry mean.
  • A Debt to Equity ratio of 4.0% means that company has $0.04 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Neuren Pharmaceuticals Ltd:

  • The MRQ is 0.040. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.040. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.040TTM0.0400.000
TTM0.040YOY0.020+0.020
TTM0.0405Y0.042-0.002
5Y0.04210Y0.121-0.078
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0400.375-0.335
TTM0.0400.396-0.356
YOY0.0200.317-0.297
5Y0.0420.425-0.383
10Y0.1210.477-0.356
3rd Party Ad. No recommendation by Penke. PLUS is ad-free.

2. Market Valuation of Neuren Pharmaceuticals Ltd

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Neuren Pharmaceuticals Ltd generates.

  • Above 15 is considered overpriced but always compare Neuren Pharmaceuticals Ltd to the Biotechnology industry mean.
  • A PE ratio of 5,605.87 means the investor is paying $5,605.87 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Neuren Pharmaceuticals Ltd:

  • The EOD is 13,898.335. Based on the earnings, the company is expensive. -2
  • The MRQ is 5,605.873. Based on the earnings, the company is expensive. -2
  • The TTM is 5,605.873. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD13,898.335MRQ5,605.873+8,292.462
MRQ5,605.873TTM5,605.8730.000
TTM5,605.873YOY-62.759+5,668.632
TTM5,605.8735Y1,110.868+4,495.006
5Y1,110.86810Y567.559+543.309
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD13,898.335-2.636+13,900.971
MRQ5,605.873-2.324+5,608.197
TTM5,605.873-2.801+5,608.674
YOY-62.759-4.414-58.345
5Y1,110.868-6.185+1,117.053
10Y567.559-6.292+573.851
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Neuren Pharmaceuticals Ltd:

  • The EOD is 1,085.439. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is 437.810. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is 437.810. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD1,085.439MRQ437.810+647.629
MRQ437.810TTM437.8100.000
TTM437.810YOY-49.012+486.822
TTM437.8105Y73.818+363.992
5Y73.81810Y28.871+44.947
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD1,085.439-3.656+1,089.095
MRQ437.810-2.911+440.721
TTM437.810-3.541+441.351
YOY-49.012-6.023-42.989
5Y73.818-8.362+82.180
10Y28.871-8.792+37.663
3rd Party Ad. No recommendation by Penke. PLUS is ad-free.
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Neuren Pharmaceuticals Ltd is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 24.80 means the investor is paying $24.80 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Neuren Pharmaceuticals Ltd:

  • The EOD is 61.490. Based on the equity, the company is expensive. -2
  • The MRQ is 24.802. Based on the equity, the company is expensive. -2
  • The TTM is 24.802. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD61.490MRQ24.802+36.688
MRQ24.802TTM24.8020.000
TTM24.802YOY12.461+12.340
TTM24.8025Y14.951+9.851
5Y14.95110Y10.433+4.518
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD61.4902.155+59.335
MRQ24.8021.883+22.919
TTM24.8022.134+22.668
YOY12.4613.019+9.442
5Y14.9513.616+11.335
10Y10.4334.009+6.424
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Neuren Pharmaceuticals Ltd.

3rd Party Ad. No recommendation by Penke. PLUS is ad-free.

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Neuren Pharmaceuticals Ltd compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.0180.0180%0.116-84%0.039-54%0.027-34%
Book Value Per Share--0.3210.3210%0.303+6%0.221+45%0.171+87%
Current Ratio--25.77225.7720%49.868-48%29.604-13%18.768+37%
Debt To Asset Ratio--0.0390.0390%0.020+93%0.040-4%0.098-60%
Debt To Equity Ratio--0.0400.0400%0.020+97%0.042-5%0.121-67%
Dividend Per Share----0%-0%-0%-0%
Eps--0.0010.0010%-0.060+4336%-0.038+2768%-0.050+3654%
Free Cash Flow Per Share--0.0180.0180%-0.077+524%-0.032+279%-0.051+380%
Free Cash Flow To Equity Per Share--0.0180.0180%0.094-81%0.052-65%0.025-28%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max--1.346--------
Intrinsic Value_10Y_min---0.222--------
Intrinsic Value_1Y_max--0.004--------
Intrinsic Value_1Y_min---0.044--------
Intrinsic Value_3Y_max--0.111--------
Intrinsic Value_3Y_min---0.114--------
Intrinsic Value_5Y_max--0.339--------
Intrinsic Value_5Y_min---0.164--------
Market Cap2557293660.000+60%1031480700.0001031480700.0000%489142420.000+111%438152242.000+135%265862528.600+288%
Net Profit Margin--0.1630.1630%-188.902+116341%-55.362+34167%-22.639+14031%
Operating Margin---0.110-0.1100%-278.976+252698%-74.692+67584%-54.258+49067%
Operating Ratio--1.1101.1100%278.976-100%80.214-99%70.109-98%
Pb Ratio61.490+60%24.80224.8020%12.461+99%14.951+66%10.433+138%
Pe Ratio13898.335+60%5605.8735605.8730%-62.759+101%1110.868+405%567.559+888%
Price Per Share19.710+60%7.9507.9500%3.770+111%3.377+135%2.049+288%
Price To Free Cash Flow Ratio1085.439+60%437.810437.8100%-49.012+111%73.818+493%28.871+1416%
Price To Total Gains Ratio1094.732+60%441.559441.5590%32.495+1259%96.459+358%51.036+765%
Quick Ratio--24.59424.5940%47.580-48%41.730-41%25.373-3%
Return On Assets--0.0550.0550%-0.193+454%-0.222+506%-0.446+915%
Return On Equity--0.0570.0570%-0.197+447%-0.228+502%-0.563+1091%
Total Gains Per Share--0.0180.0180%0.116-84%0.039-54%0.027-34%
Usd Book Value--27140981.40027140981.4000%25616507.800+6%18737190.160+45%14483816.128+87%
Usd Book Value Change Per Share--0.0120.0120%0.076-84%0.025-54%0.018-34%
Usd Book Value Per Share--0.2090.2090%0.197+6%0.144+45%0.112+87%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps--0.0010.0010%-0.039+4336%-0.025+2768%-0.033+3654%
Usd Free Cash Flow--1537525.6001537525.6000%-6512948.000+524%-2744966.120+279%-4301731.225+380%
Usd Free Cash Flow Per Share--0.0120.0120%-0.050+524%-0.021+279%-0.033+380%
Usd Free Cash Flow To Equity Per Share--0.0120.0120%0.061-81%0.034-65%0.016-28%
Usd Market Cap1668889842.516+60%673144304.820673144304.8200%319214343.292+111%285938153.129+135%173501886.164+288%
Usd Price Per Share12.863+60%5.1885.1880%2.460+111%2.204+135%1.337+288%
Usd Profit--1543399.0001543399.0000%-5054387.000+427%-2841420.400+284%-4143281.216+368%
Usd Revenue--9497287.8009497287.8000%26756.600+35395%3770983.840+152%2677617.800+255%
Usd Total Gains Per Share--0.0120.0120%0.076-84%0.025-54%0.018-34%
 EOD+4 -4MRQTTM+0 -0YOY+19 -145Y+21 -1210Y+22 -11

4.2. Fundamental Score

Let's check the fundamental score of Neuren Pharmaceuticals Ltd based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-1513,898.335
Price to Book Ratio (EOD)Between0-161.490
Net Profit Margin (MRQ)Greater than00.163
Operating Margin (MRQ)Greater than0-0.110
Quick Ratio (MRQ)Greater than124.594
Current Ratio (MRQ)Greater than125.772
Debt to Asset Ratio (MRQ)Less than10.039
Debt to Equity Ratio (MRQ)Less than10.040
Return on Equity (MRQ)Greater than0.150.057
Return on Assets (MRQ)Greater than0.050.055
Total6/10 (60.0%)

4.3. Technical Score

Let's check the technical score of Neuren Pharmaceuticals Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5039.595
Ma 20Greater thanMa 5021.428
Ma 50Greater thanMa 10022.747
Ma 100Greater thanMa 20018.235
OpenGreater thanClose19.880
Total3/5 (60.0%)



Latest Balance Sheet

Balance Sheet of 2022-12-31. Currency in AUD. All numbers in thousands.

Summary
Total Assets43,267
Total Liabilities1,678
Total Stockholder Equity41,589
 As reported
Total Liabilities 1,678
Total Stockholder Equity+ 41,589
Total Assets = 43,267

Assets

Total Assets43,267
Total Current Assets43,246
Long-term Assets21
Total Current Assets
Cash And Cash Equivalents 40,180
Net Receivables 1,089
Other Current Assets 1,977
Total Current Assets  (as reported)43,246
Total Current Assets  (calculated)43,246
+/-0
Long-term Assets
Property Plant Equipment 21
Long-term Assets  (as reported)21
Long-term Assets  (calculated)21
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities1,678
Long-term Liabilities258
Total Stockholder Equity41,589
Total Current Liabilities
Accounts payable 258
Other Current Liabilities 1,420
Total Current Liabilities  (as reported)1,678
Total Current Liabilities  (calculated)1,678
+/-0
Long-term Liabilities
Long-term Liabilities  (as reported)258
Long-term Liabilities  (calculated)0
+/- 258
Total Stockholder Equity
Common Stock167,740
Retained Earnings -118,693
Accumulated Other Comprehensive Income -7,458
Total Stockholder Equity (as reported)41,589
Total Stockholder Equity (calculated)41,589
+/-0
Other
Capital Stock167,740
Cash And Equivalents37,876
Cash and Short Term Investments 40,180
Common Stock Shares Outstanding 107,057
Liabilities and Stockholders Equity 43,267
Net Debt -40,180
Net Invested Capital 41,589
Net Tangible Assets 41,589
Net Working Capital 41,568
Property Plant and Equipment Gross 21



Balance Sheet

Currency in AUD. All numbers in thousands.

 Trend2022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-312012-12-312011-12-312010-12-312009-12-312008-12-312007-12-312006-12-312005-12-312004-12-312003-12-312002-12-312001-12-312000-12-31
> Total Assets 
4,584
5,149
3,332
696
12,962
35,205
19,524
14,586
8,545
10,285
5,717
11,137
8,482
26,413
22,106
16,904
6,210
17,944
26,642
14,406
24,953
40,056
43,267
43,26740,05624,95314,40626,64217,9446,21016,90422,10626,4138,48211,1375,71710,2858,54514,58619,52435,20512,9626963,3325,1494,584
   > Total Current Assets 
0
0
0
0
2,174
25,035
10,350
1,281
1,522
5,263
1,812
7,594
5,267
25,997
21,787
16,676
6,053
16,086
26,639
14,396
24,943
40,044
43,246
43,24640,04424,94314,39626,63916,0866,05316,67621,78725,9975,2677,5941,8125,2631,5221,28110,35025,0352,1740000
       Cash And Cash Equivalents 
4,109
3,773
1,928
116
317
23,303
9,459
1,137
1,354
3,426
1,485
7,489
5,137
24,336
20,824
16,642
5,051
4,706
23,576
13,844
24,188
36,783
40,180
40,18036,78324,18813,84423,5764,7065,05116,64220,82424,3365,1377,4891,4853,4261,3541,1379,45923,3033171161,9283,7734,109
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2,272
9,138
19,838
13,024
23,959
0
0
0023,95913,02419,8389,1382,2720000000000000000
       Net Receivables 
0
0
180
16
1,014
1,561
792
112
93
281
43
18
11
1,618
963
34
21
692
942
552
755
1,424
1,089
1,0891,42475555294269221349631,618111843281931127921,5611,0141618000
   > Long-term Assets 
0
0
0
0
10,788
10,169
9,174
13,305
7,022
5,022
3,906
3,543
3,215
416
319
228
157
1,858
3
10
10
12
21
2112101031,8581572283194163,2153,5433,9065,0227,02213,3059,17410,16910,7880000
       Property Plant Equipment 
329
885
860
0
66
80
270
300
79
41
17
5
25
23
29
11
12
7
2
10
10
12
21
21121010271211292325517417930027080660860885329
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,374
0
0
0
0
0
000001,37400000000000000000
       Intangible Assets 
0
0
0
0
10,722
10,089
8,903
13,005
6,944
4,981
3,888
3,538
3,189
393
290
217
145
73
1
0
0
0
0
00001731452172903933,1893,5383,8884,9816,94413,0058,90310,08910,7220000
       Other Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,778
0
0
0
0
0
000001,77800000000000000000
> Total Liabilities 
7,616
16,781
1,509
15,413
4,196
3,046
3,377
7,035
2,972
2,937
2,184
1,684
2,141
2,058
3,028
2,502
2,027
1,580
1,973
559
753
803
1,678
1,6788037535591,9731,5802,0272,5023,0282,0582,1411,6842,1842,9372,9727,0353,3773,0464,19615,4131,50916,7817,616
   > Total Current Liabilities 
614
1,476
1,509
1,689
4,196
3,046
3,310
6,958
2,934
2,522
2,177
1,684
2,128
2,058
3,028
2,502
2,027
1,580
1,973
559
753
803
1,678
1,6788037535591,9731,5802,0272,5023,0282,0582,1281,6842,1772,5222,9346,9583,3103,0464,1961,6891,5091,476614
       Short-term Debt 
0
0
0
0
0
0
13
3,463
23
9
454
0
0
0
0
0
0
9,138
0
0
0
0
0
000009,1380000004549233,46313000000
       Accounts payable 
216
815
1,102
615
1,184
1,283
2,454
2,729
2,267
2,443
1,753
1,596
2,168
2,012
2,755
1,771
1,035
723
1,335
340
167
245
258
2582451673401,3357231,0351,7712,7552,0122,1681,5961,7532,4432,2672,7292,4541,2831,1846151,102815216
       Other Current Liabilities 
398
661
407
674
3,103
1,848
1,109
1,091
1,015
536
392
469
408
209
273
731
992
857
638
219
586
558
1,420
1,4205585862196388579927312732094084693925361,0151,0911,1091,8483,103674407661398
   > Long-term Liabilities 
0
0
0
0
0
0
67
78
38
414
7
0
13
0
0
0
0
0
0
340
167
245
258
2582451673400000001307414387867000000
       Other Liabilities 
0
0
0
0
0
0
75
60
34
22
9
0
17
0
0
0
0
0
0
0
0
0
0
0000000000170922346075000000
> Total Stockholder Equity
0
0
1,823
0
8,735
19,884
16,147
7,551
5,573
7,490
3,574
9,498
6,484
24,559
19,299
14,402
4,183
16,364
24,669
13,847
24,200
39,253
41,589
41,58939,25324,20013,84724,66916,3644,18314,40219,29924,5596,4849,4983,5747,4905,5737,55116,14719,8848,73501,82300
   Common Stock
0
0
0
0
19,529
39,115
44,528
47,581
57,522
56,131
52,280
61,144
64,177
101,997
104,363
111,912
112,829
121,136
126,426
126,426
145,567
167,578
167,740
167,740167,578145,567126,426126,426121,136112,829111,912104,363101,99764,17761,14452,28056,13157,52247,58144,52839,11519,5290000
   Retained Earnings Total Equity00000000000000000000000
   Accumulated Other Comprehensive Income 
0
0
0
0
-277
-325
522
676
2,129
2,915
4,545
6,361
7,878
9,854
-916
-7,764
-10,292
-7,332
-8,497
-8,503
-10,284
-9,448
-7,458
-7,458-9,448-10,284-8,503-8,497-7,332-10,292-7,764-9169,8547,8786,3614,5452,9152,129676522-325-2770000
   Capital Surplus 00000000000000000000000
   Treasury Stock00000000000000000000000
   Other Stockholders Equity -10,680-9,448-10,284-8,503-8,497-7,332-10,292-10,653-916-1,7250000000000000



Balance Sheet

Currency in AUD. All numbers in thousands.




Cash Flow

Currency in AUD. All numbers in thousands.




Income Statement

Currency in AUD. All numbers in thousands.